These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 30487133)

  • 21. Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.
    Keller MD; Neppl C; Irmak Y; Hall SR; Schmid RA; Langer R; Berezowska S
    Mod Pathol; 2018 Jan; 31(1):101-110. PubMed ID: 28884747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A High PD-L1 Expression in Pulmonary Pleomorphic Carcinoma Correlates with Parietal-pleural Invasion and Might Predict a Poor Prognosis.
    Naito M; Tamiya A; Takeda M; Taniguchi Y; Saijo N; Naoki Y; Okishio K; Yoon H; Kasai T; Matsumura A; Atagi S
    Intern Med; 2019 Apr; 58(7):921-927. PubMed ID: 30568128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
    Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
    J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
    Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
    Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma.
    Moratin J; Metzger K; Safaltin A; Herpel E; Hoffmann J; Freier K; Hess J; Horn D
    Head Neck; 2019 Aug; 41(8):2484-2491. PubMed ID: 30821864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
    Li W; Song P; Guo L; Liu X; Guo C; Ying J; Gao S
    Thorac Cancer; 2019 Feb; 10(2):175-182. PubMed ID: 30536734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
    Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
    Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
    BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Pai SI; Cohen EEW; Lin D; Fountzilas G; Kim ES; Mehlhorn H; Baste N; Clayburgh D; Lipworth L; Resteghini C; Shara N; Fujii T; Zhang J; Stokes M; Wang H; Twumasi-Ankrah P; Wildsmith S; Khaliq A; Melillo G; Shire N
    J Transl Med; 2019 Dec; 17(1):429. PubMed ID: 31878938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients.
    Wyss J; Dislich B; Koelzer VH; Galván JA; Dawson H; Hädrich M; Inderbitzin D; Lugli A; Zlobec I; Berger MD
    Clin Colorectal Cancer; 2019 Mar; 18(1):e20-e38. PubMed ID: 30389315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1
    Ma SR; Liu JF; Jia R; Deng WW; Jia J
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
    Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression.
    Chen MF; Chen PT; Chen WC; Lu MS; Lin PY; Lee KD
    Oncotarget; 2016 Feb; 7(7):7913-24. PubMed ID: 26761210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
    Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
    Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas.
    Yeong J; Zhao Z; Lim JCT; Li H; Thike AA; Koh VCY; Teh BT; Kanesvaran R; Toh CK; Tan PH; Khor LY
    J Clin Pathol; 2020 Aug; 73(8):463-469. PubMed ID: 31980560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
    Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
    Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer.
    Govindarajan R; Gujja S; Siegel ER; Batra A; Saeed A; Lai K; James JD; Fogel BJ; Williamson S
    Am J Clin Oncol; 2018 Jul; 41(7):638-642. PubMed ID: 27849650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.
    Manson QF; Schrijver WAME; Ter Hoeve ND; Moelans CB; van Diest PJ
    Clin Exp Metastasis; 2019 Feb; 36(1):29-37. PubMed ID: 30547271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinicopathological and prognostic significance of PD-L1 expression in oral squamous cell carcinoma: a meta analysis].
    Zou B; Xu K; Liu XB; Fan QC; Yuan DY
    Shanghai Kou Qiang Yi Xue; 2018 Feb; 27(1):100-105. PubMed ID: 29946653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.